4-[(4-methoxyphenyl)-phenylmethyl]piperidine-1-carbaldehyde | 107453-88-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[(4-methoxyphenyl)-phenylmethyl]piperidine-1-carbaldehyde
• CAS: 107453-88-3
• 化学式: C₂₀H₂₃NO₂
• 分子量: 309.408
• InChiKey: PRLVAQXTYJQXPK-UHFFFAOYSA-N

物化性质

• 沸点：
  481.5±28.0 °C(Predicted)
• 密度：
  1.144±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  23.0
• 可旋转键数：
  5.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  29.54
• 氢给体数：
  0.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  4-[(4-methoxyphenyl)-phenylmethyl]piperidine-1-carbaldehyde 在 光气 、 氢溴酸 、 potassium carbonate 、 三乙胺 作用下， 反应 5.0h， 生成 4-<(4-hydroxyphenyl)phenylmethyl>-1-<(octylimino)methyl>piperidine
  参考文献：
  名称：

  Antisecretory activity of human, dog, and rat metabolites of fenoctimine

  摘要：

  Fenoctimine (1a), a nonanticholinergic inhibitor of gastric acid secretion in dogs and rats, was evaluated as a gastric antisecretory agent in humans. In humans it exhibited weak antisecretory activity and caused anticholinergic-like side effects such as dry mouth and nasal passages. Studies of the metabolic fate of fenoctimine in humans, dogs, and rats provided structures of the resultant metabolites. These were synthesized and tested for antisecretory and anticholinergic activity. The human metabolites were all less active than fenoctimine as antisecretory agents, and some displayed significant anticholinergic activity. These results suggest that the unexpectedly weak effect of fenoctimine as a gastric antisecretory agent in humans, as well as anticholinergic effects, may be due to its extensive metabolism, which is different from that seen in dog and rat.

  DOI：

  10.1021/jm00388a025
• 作为产物：
  描述：

  甲酸 、 4-<(4-methoxyphenyl)phenylmethyl>piperidine 在 乙酸酐 作用下， 以22.4 g的产率得到4-[(4-methoxyphenyl)-phenylmethyl]piperidine-1-carbaldehyde
  参考文献：
  名称：

  Antisecretory activity of human, dog, and rat metabolites of fenoctimine

  摘要：

  Fenoctimine (1a), a nonanticholinergic inhibitor of gastric acid secretion in dogs and rats, was evaluated as a gastric antisecretory agent in humans. In humans it exhibited weak antisecretory activity and caused anticholinergic-like side effects such as dry mouth and nasal passages. Studies of the metabolic fate of fenoctimine in humans, dogs, and rats provided structures of the resultant metabolites. These were synthesized and tested for antisecretory and anticholinergic activity. The human metabolites were all less active than fenoctimine as antisecretory agents, and some displayed significant anticholinergic activity. These results suggest that the unexpectedly weak effect of fenoctimine as a gastric antisecretory agent in humans, as well as anticholinergic effects, may be due to its extensive metabolism, which is different from that seen in dog and rat.

  DOI：

  10.1021/jm00388a025

文献信息

• SCOTT M. K.; JACOBY H. I.; BONFILIO A. C.; CORCORAN T. W.; LOPEZ I. S., J. MED. CHEM., 30,(1987) N 5, 894-899
  作者：SCOTT M. K.、 JACOBY H. I.、 BONFILIO A. C.、 CORCORAN T. W.、 LOPEZ I. S.

  DOI：——

  日期：——